SIGA Technologies(US:SIGA)2025-11-06 21:06Financial Performance - For the first nine months of 2025, SIGA generated $86 million in product revenues and $33 million in pre-tax operating income[3]. - Product sales for the three months ended September 30, 2025, were $0.9 million, compared to $8.9 million for the same period in 2024, while total revenues were $2.6 million compared to $10.0 million in 2024[4]. - For the nine months ended September 30, 2025, product sales reached $85.8 million, up from $53.5 million in 2024, with total revenues increasing to $90.8 million from $57.3 million[4]. - The net income for the nine months ended September 30, 2025, was $28.7 million, compared to $13.5 million in 2024, resulting in a diluted income per share of $0.40 versus $0.19[4]. - Total revenues for the three months ended September 30, 2025, were $2,620,000, a decrease from $10,009,781 in the same period of 2024[17]. - Product sales and supportive services generated $889,748 in Q3 2025, compared to $8,942,875 in Q3 2024, reflecting a significant decline[17]. - The company reported a net income of $28,709,061 for the nine months ended September 30, 2025, compared to $13,453,901 in the same period of 2024[17]. Funding and Development - The company received $13 million in funding for the TPOXX pediatric development program under the BARDA 19C contract, in addition to $14 million for manufacturing activities, totaling $27 million in development funding added during Q2 2025[11]. - SIGA delivered $53 million of oral TPOXX revenues and $26 million of IV TPOXX revenues to the U.S. Strategic National Stockpile in the first nine months of 2025[11]. - A procurement order for $26 million of IV TPOXX was received from the U.S. Government under the BARDA contract in March 2025[11]. Cash and Assets - As of September 30, 2025, SIGA's cash and cash equivalents totaled approximately $172 million, an increase from $155 million as of December 31, 2024[16]. - Total assets decreased to $231.6 million as of September 30, 2025, from $244.3 million as of December 31, 2024[16]. Dividends and Shareholder Returns - The company declared a special cash dividend of $0.60 per share on April 8, 2025, which was paid on May 15, 2025[7]. Operating Expenses and Losses - Research and development expenses increased to $7,053,985 in Q3 2025, up from $3,024,593 in Q3 2024, indicating a 133% rise[17]. - Operating loss for the three months ended September 30, 2025, was $(10,222,579), compared to an operating income of $542,087 in the same period of 2024[17]. - Net and comprehensive loss for Q3 2025 was $(6,365,819), contrasting with a net income of $1,343,945 in Q3 2024[17]. - Basic loss per share for Q3 2025 was $(0.09), compared to a basic income per share of $0.02 in Q3 2024[17]. - Total operating expenses for the nine months ended September 30, 2025, were $57,578,927, up from $44,353,199 in the same period of 2024[17]. Shares Outstanding - Weighted average shares outstanding for basic shares increased slightly to 71,604,956 in Q3 2025 from 71,368,585 in Q3 2024[17]. Other Income - Other income for the three months ended September 30, 2025, was $1,866,693, compared to $1,330,505 in Q3 2024, showing an increase of 40%[17].